Advertisement

Topics

Companies Related to "Microdosing Successful Ocular Meds Delivery" [Most Relevant Company Matches] RSS

13:33 EST 10th December 2018 | BioPortfolio

Here are the most relevant search results for "Microdosing Successful Ocular Meds Delivery" found in our extensive corporate database of over 50,000 company records.

Showing "Microdosing Successful Ocular Meds Delivery" Companies 1–25 of 2,600+

Relevant

Meds For America Inc.,

Welcome to Meds For America Inc., your safe, easy, and affordable source for prescription medication.Meds For America Inc. can help you manage both your health and your budget. As one of North America’s trusted alternatives to the high cost of prescription medication, Meds For America Inc. offers a prescription management service delivering prescriptions at prices well below those found at your ...


Abbott RX Meds

Abbott RX Meds is a safe, private and convenient source for sourcing prescriptions for FDA approved prescription medications discreetly in the privacy of your home. Inform yourself about options and choices All who visit this site are encouraged to read the information here and learn about his or her treatment options. Although it is prudent to use a doctor as the first source for treatment inform...

Ocular Therapeutix, Inc. 

Ocular Therapeutix, Inc. (NASDAQ: OCUL) is a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Ocular Therapeutix's lead product candidates are in Phase 3 clinical development for post-surgical ocular inflammation an...


Ora, Inc.

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Ocular Therapeutix’s lead product candidates are in Phase 3 clinical development for post-surgical ocular inflammation and pain and a...

Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc. is a privately held company based in Bedford, MA, focused on the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology. Ocular Therapeutix is focusing on development of drug-eluting punctum plugs for treatment of glaucoma and post-operative inflammation and pain, injectable d...

Anti-Aging-Meds.com

Nil

Mati Therapeutics, Inc.

Mati is developing the Evolute® sustained ocular drug delivery platform, which Mati believes has the potential to treat a range of ocular indications. The platform utilizes a device called a punctal plug, which is easily inserted into a patient’s punctum. The device has already been approved to treat dry eye syndrome, but Mati is the first to condu...

Ocular Therapeutix™, Inc.

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel-based formulation technology. Ocular Therapeutix’s lead product candidate, DEXTENZA™ (dexamethasone insert) 0.4 mg for intracanalicular ...

Kala Pharmaceuticals Inc.

Kala Pharmaceuticals, Inc. is advancing innovative treatments for ocular diseases addressing significant needs in both front and back of the eye based on the company’s proprietary Mucus Penetrating Particle (MPP) platform technology. Kala’s topical ocular MPP formulations enhance penetration into ocular tissue by facilitating penetration through the ...

Sirion Therapeutics, Inc.

Herpetic Keratitis is the number one infectious cause of corneal blindness in the U.S. Herpes simplex virus infections are very common, with nearly 60% of the US population showing evidence of infection by age five. Approximately 1% of infected patients develop ocular outbreaks, with 20,000 primary cases of ocular herpes diagnosed in the US each year. After the primary infection, ocular HSV typic...

Mati Therapeutics Inc.

Mati is developing PPDS, a sustained release ocular drug delivery platform that Mati believes has the potential to treat a range of ocular indications. The platform utilizes a device called a punctal plug, which is inserted into a patient’s tear duct (or punctum). The device is already approved to treat dry eye syndrome, but Mati is the first to condu...

Scintipharma, Inc.

SCINTIPHARMA, Inc. is a privately held company focused on problem solving in the field of pharmaceutical dosage form development. The company's main objective is to provide services to the pharmaceutical industry for the optimization of drug delivery systems. The primary mission is improved delivery of currently marketed and potentially marketable therapeutic agents in the gastrointestinal tract a...

Ocular Surface Center, P.A.

Ocular Surface Foundation (OSF) is a non-profit public medical research foundation (501c3) established in 1999, and carries s single mission of promoting the spread of the knowledge and skills that are important for treating ocular surface diseases. Under the leadership of the President, Billy K. Yeh, M.D., Ph.D., OSF supports research and educational programs that may create a differentiable valu...

PreEmptive Meds, Inc.

Founded in 2006 by seasoned pharmaceutical executives and a world-class Medical Board, PMI is the premier therapeutic company that offers proprietary, branded, clinically proven, 100% Natural formulations as effective alternatives to prescriptions.

MacuSight, Inc.

MacuSight is a privately-held pharmaceutical company focused on developing innovative therapeutics for the treatment of severe ocular diseases and conditions. The company is dedicated to preserving patients' vision by identifying known, highly-potent and broad-acting small molecule drug compounds that may possess efficacy in treating and/or preventing diseases or conditions of the eye. As part...

AsclepiX Therapeutics, Inc.

AsclepiX Therapeutics is transforming the treatment of ocular diseases and cancer with a singular focus on a novel peptide platform with the power to inhibit and potentially even reverse disease progression. The mechanism of action of AXT107 targets multiple pathways, including vascular endothelial growth factor A (VEGF-A) and Tie2, two factors that promot...

Pharmaceutical Profiles Group

Pharmaceutical Profiles is a unique Phase 0 / I / IIa CRO which provides novel solutions in early clinical development. Since its inception in 1990, Pharmaceutical Profiles’ mission has been to improve the decision-making process by offering innovative services that help select the right molecules and deselect the wrong ones in early drug development.Around 40% of drug candidates fail to progres...

iVeena Delivery Systems, Inc.

iVeena Delivery Systems, Inc. (iVeena) is a privately held biopharmaceutical company that develops innovative ophthalmology products. iVeena utilizes a proprietary intracapsular drug delivery platform to enhance a medication’s ocular bioavailability to anterior and posterior eye segments. The lead product delivers dexamethasone to treat post-cataract ...

SOOFT italia S.p.A.

SOOFT italia S.p.A. a Company of OOgroup , is an Italian pharmaceutical firm specialized in the research of new solutions , in carrying out and marketing of products for general and specific eyes health.SOOFT italia S.p.A. is mainly involved in the most common ocular pathologies, ranging from anterior segment (dry eye, ocular inflammations, periocular hygi...

C T O CLINICA TERAPUTICA OCULAR

Nil

Ocular Services on Demand LLC

Clearside Biomedical

Clearside Biomedical is an ophthalmic company specializing in the research, development and commercialization of therapeutic products through a proprietary ocular microinjection platform that targets the individual compartments of the eye. Clearside Biomedical raised a $4 million series A from Hatteras Venture Partners, Georgia Research Alliance Venture Fu...

Centre for Ocular Research & Education

Graybug Vision, Inc.

Graybug Vision is developing novel products for the treatment of people with ocular diseases. The company’s proprietary injectable products are designed to enable less frequent administration and to reduce the burden of treatment for patients with ocular diseases. The company’s lead product, GB-102, has the potential for twice per year injections to ...

Ceregene

Ceregene, Inc. is a San Diego-based biotechnology company focused on the delivery of neurotrophic (or nervous system growth) factors for the treatment of neurodegenerative and retinal disorders using gene delivery. Ceregene's clinical programs include CERE-110, an AAV2 based vector expressing nerve growth factor currently in a multi-center, controlled Phase 2 study for the treatment of Alzheimer's...


More From BioPortfolio on "Microdosing Successful Ocular Meds Delivery"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks